Is fosfomycin still a viable treatment option for a patient with a urinary tract infection caused by carbapenemase-producing Enterobacter cloacae complex?

Fosfomycin for Enterobacter cloacae Complex UTI

Fosfomycin can be used for Enterobacter cloacae complex urinary tract infections, but ONLY if susceptibility testing confirms the isolate is susceptible to fosfomycin or if synergy testing demonstrates synergistic activity in combination therapy. 1

Critical Decision Points

For Uncomplicated Lower UTI (Cystitis)

• Oral fosfomycin 3g single dose is appropriate if the isolate is susceptible and the infection is limited to the bladder 2, 3
• This applies specifically to uncomplicated cystitis in women without systemic signs of infection 2
• Do NOT use fosfomycin for pyelonephritis or complicated UTIs with Enterobacter species, as efficacy data is insufficient for upper tract infections 2

For Carbapenem-Resistant Enterobacter cloacae Complex

• Intravenous fosfomycin-containing combination therapy is recommended when the isolate is carbapenem-resistant AND susceptibility/synergy testing confirms activity 1
• Fosfomycin should be used in combination (not as monotherapy) for carbapenem-resistant organisms 1
• Common combination partners include aminoglycosides, tigecycline, or polymyxins based on susceptibility 1

Important Caveats and Pitfalls

Susceptibility Testing is Mandatory

• You must confirm fosfomycin susceptibility before treatment - do not assume activity based on species alone 1
• Enterobacter cloacae complex can harbor resistance mechanisms (including FosA-like genes) that confer fosfomycin resistance 1
• In vitro studies show Enterobacter cloacae isolates with MIC >16 mg/L are not reliably killed by standard fosfomycin dosing 4

Resistance Emergence Risk

• Fosfomycin monotherapy carries significant risk of resistance emergence during treatment 4
• For carbapenem-resistant isolates, combination therapy is essential to prevent resistance development 1

Patient-Specific Contraindications

Avoid fosfomycin in patients with: 1, 2

• Hypernatremia
• Cardiac insufficiency
• Severe renal insufficiency (though standard dosing acceptable if eGFR ≥30 mL/min/1.73 m²) 2

Clinical Monitoring

• Monitor electrolytes during treatment, as fosfomycin can cause hypokalemia, hypocalcemia, hypomagnesemia, and hypernatremia 2
• If symptoms do not improve within 2-3 days or recur within 2 weeks, obtain repeat culture and consider alternative agents 2

Treatment Algorithm

Step 1: Confirm infection location (lower vs upper tract) 2

Step 2: Obtain susceptibility testing for fosfomycin 1

Step 3: If susceptible and uncomplicated cystitis → oral fosfomycin 3g single dose 2, 3

Step 4: If carbapenem-resistant → IV fosfomycin-containing combination therapy (not monotherapy) 1

Step 5: If pyelonephritis or complicated UTI → choose alternative agent (fluoroquinolones, β-lactams, or carbapenems based on susceptibility) 2